Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
CSPC Pharmaceutical Group ( (HK:1093) ) has issued an update.
CSPC Pharmaceutical Group’s subsidiary, CSPC Megalith Biopharmaceutical, has entered into an exclusive license agreement with Radiance Biopharma for the development and commercialization of their anti-cancer drug SYS6005 in various international markets. This agreement allows CSPC to receive significant upfront and potential milestone payments, enhancing its position in the global pharmaceutical market and potentially advancing cancer treatment options.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-based company involved in the pharmaceutical industry, primarily focused on developing innovative drug products and therapies. The company specializes in creating biopharmaceuticals and has a strong market presence in the development of antibody-drug conjugates (ADCs) for cancer treatment.
YTD Price Performance: 3.73%
Average Trading Volume: 8,854
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.04B
Learn more about 1093 stock on TipRanks’ Stock Analysis page.
